Results 1 to 10 of about 25,852 (227)

Adding Bortezomib and Bendamustine to High‐Dose Melphalan in Autologous Haematopoietic Stem Cell Transplantation for Relapsed Multiple Myeloma—A Single Centre Retrospective Study [PDF]

eJHaem
Introduction High‐dose melphalan (HDM) followed by autologous haematopoietic stem cell transplantation (ASCT) remains the standard of care for eligible patients with multiple myeloma (MM).
Thomas Silfverberg, Honar Cherif, Emma Smitt, Kristina Carlson   +3 more
doaj   +2 more sources

Clinical Impact of Melphalan Pharmacokinetics on Transplantation Outcomes in Children Undergoing Hematopoietic Stem Cell Transplantation

Cell Transplantation, 2022
Melphalan is widely used for hematopoietic stem cell transplantation (HSCT) conditioning. However, the relationship between its pharmacokinetic (PK) and transplantation outcomes in children has not been thoroughly investigated.
Ryo Maemura, Manabu Wakamatsu, Kana Matsumoto, Hirotoshi Sakaguchi, Nao Yoshida, Asahito Hama, Taro Yoshida, Shunsuke Miwata, Hironobu Kitazawa, Kotaro Narita, Shinsuke Kataoka, Daisuke Ichikawa, Motoharu Hamada, Rieko Taniguchi, Kyogo Suzuki, Nozomu Kawashima, Eri Nishikawa, Atsushi Narita, Yusuke Okuno, Nobuhiro Nishio, Koji Kato, Seiji Kojima, Kunihiko Morita, Hideki Muramatsu, Yoshiyuki Takahashi   +24 more
doaj   +1 more source

Lipid-nanoparticles-based co-delivery of black phosphorus quantum dots and melphalan by photothermal therapy combined with chemotherapy for retinoblastoma

Polymer Testing, 2023
Melphalan is an efficient chemotherapeutic agent for retinoblastoma (RB) in clinical practice. However, the problems of drug resistance and poor prognosis caused by long-term treatment of melphalan should not be ignored.
Shijing Wang, Pengxue Wei, Yujun Zhang, Shaochong Zhang   +3 more
doaj   +1 more source

Melphalan induces cardiotoxicity through oxidative stress in cardiomyocytes derived from human induced pluripotent stem cells

Stem Cell Research & Therapy, 2020
Background Treatment-induced cardiotoxicity is a leading noncancer-related cause of acute and late onset morbidity and mortality in cancer patients on antineoplastic drugs such as melphalan—increasing clinical case reports have documented that it could ...
Rui Liu, Dong Li, Fangxu Sun, Antonio Rampoldi, Joshua T. Maxwell, Ronghu Wu, Peter Fischbach, Sharon M. Castellino, Yuhong Du, Haian Fu, Anant Mandawat, Chunhui Xu   +11 more
doaj   +1 more source

A case report: high dose melphalan as a conditioning regimen for multiple myeloma induces sinus arrest

Cardio-Oncology, 2020
High dose melphalan is commonly used as a conditioning regimen for autologous stem cell transplantation in multiple myeloma. There are reports of adverse cardiac events with melphalan manifested by supraventricular tachycardia and atrial fibrillation ...
Liang-Liang Ma, Ying Liu, Si-Xun Jia, Hai-Chen Lv, Mei-Yun Fang, Yun-Long Xia   +5 more
doaj   +1 more source

Melphalan 140 mg/m2 or 200 mg/m2 for autologous transplantation in myeloma: results from the Collaboration to Collect Autologous Transplant Outcomes in Lymphoma and Myeloma (CALM) study. A report by the EBMT Chronic Malignancies Working Party

Haematologica, 2018
Melphalan at a dose of 200 mg/m2 is standard conditioning prior to autologous hematopoietic stem cell transplantation for multiple myeloma, but a dose of 140 mg/m2 is often used in clinical practice in patients perceived to be at risk of excess toxicity.
Holger W. Auner, Simona Iacobelli, Giulia Sbianchi, Cora Knol-Bout, Didier Blaise, Nigel H. Russell, Jane F. Apperley, David Pohlreich, Paul V. Browne, Guido Kobbe, Cecilia Isaksson, Stig Lenhoff, Christof Scheid, Cyrille Touzeau, Esa Jantunen, Achilles Anagnostopoulos, Ibrahim Yakoub-Agha, Alina Tanase, Nicolaas Schaap, Wieslaw Wiktor-Jedrzejczak, Marta Krejci, Stefan O. Schönland, Curly Morris, Laurent Garderet, Nicolaus Kröger   +24 more
doaj   +1 more source

4530 Elucidating the Influence of Chemotherapy (melphalan) and /or C. difficile toxin B Exposure on Beta-catenin Protein Expression in Caco-2 Monolayers

Journal of Clinical and Translational Science, 2020
OBJECTIVES/GOALS: We previously reported that genetic polymorphisms in the beta-catenin gene (CTNNB) are associated with the development of Clostridiodes difficile colitis during autologous stem cell transplantation (https://www-ncbi-nlm-nih-gov.proxy ...
Jailene Canales, Alison Weiss, Senu Apewokin   +2 more
doaj   +1 more source

Modulation of cell metabolic pathways and oxidative stress signaling contribute to acquired melphalan resistance in multiple myeloma cells. [PDF]

PLoS ONE, 2015
Alkylating agents are widely used chemotherapeutics in the treatment of many cancers, including leukemia, lymphoma, multiple myeloma, sarcoma, lung, breast and ovarian cancer.
Kamila Anna Zub, Mirta Mittelstedt Leal de Sousa, Antonio Sarno, Animesh Sharma, Aida Demirovic, Shalini Rao, Clifford Young, Per Arne Aas, Ida Ericsson, Anders Sundan, Ole Nørregaard Jensen, Geir Slupphaug   +11 more
doaj   +1 more source

Busulfan 12 mg/kg plus melphalan 140 mg/m2 versus melphalan 200 mg/m2 as conditioning regimens for autologous transplantation in newly diagnosed multiple myeloma patients included in the PETHEMA/GEM2000 study

Haematologica, 2010
Background The aim of this study was to compare the long-term safety and efficacy of oral busulfan 12 mg/kg plus melphalan 140 mg/m2 and melphalan 200 mg/m2 as conditioning regimens for autologous stem cell transplantation in newly diagnosed patients ...
Juan José Lahuerta, Maria Victoria Mateos, Joaquin Martínez-López, Carlos Grande, Javier de la Rubia, Laura Rosiñol, Anna Sureda, José García-Laraña, Joaquín Díaz-Mediavilla, Miguel T. Hernández-García, Dolores Carrera, Joan Besalduch, Felipe de Arriba, Albert Oriol, Lourdes Escoda, Javier García-Frade, Concepción Rivas-González, Adrían Alegre, Joan Bladé, Jesús F. San Miguel   +19 more
doaj   +1 more source

Rational Targeting of Cdc42 Overcomes Drug Resistance of Multiple Myeloma

Frontiers in Oncology, 2019
Multiple myeloma (MM) drug resistance highlights a need for alternative therapeutic strategies. In this study, we show that CASIN, a selective inhibitor of cell division cycle 42 (Cdc42) GTPase, inhibited proliferation and survival of melphalan ...
Phuong Nguyen, Phuong Nguyen, Jayati Chakrabarti, Jayati Chakrabarti, Yuan Li, Yuan Li, Khalid W. Kalim, Khalid W. Kalim, Mengnan Zhang, Lin Zhang, Yi Zheng, Yi Zheng, Fukun Guo, Fukun Guo   +13 more
doaj   +1 more source